Advanced search
Publication Cover
Expert Review of Vaccines Volume 2, 2003 - Issue 1
Submit an article Journal homepage
32
Views
7
CrossRef citations to date
0
Altmetric
Review

Genetic engineering of pollen allergens for hayfever immunotherapy

Prem L Bhalla Plant Molecular Biology and Biotechnology Laboratory, Institute of Land and Food Resources, The University of Melbourne, Parkville, Victoria 3010, Australia
Pages 75-84 | Published online: 09 Jan 2014

Referance

  • Miyamoto T Advances in Allergology and Clinical Immunology Godard P, Bousquet, J, Michel FB (Eds). The Parthenon Publishing Group, Cornforth, UK (1992).
  • Burney P, Bousquet J, Blumenthal M etal Evidence for an increase in atopic disease and possible cause. Gin. Exp. Allergy 23, 484–492 (1993).
  • Valenta R. The future of antigen-specific immunotherapy of allergy. Nat. Rev Immunol 2, 446–453 (2002). Excellent overview of allergy immunotherapy strategies.
  • Noon L. Prophylactic inoculation for hay fever. Lancet 1,1572–1573 (1911).
  • Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by anti-allergenic drugs. Br. Med. J 302, 265–269 (1991).
  • Grammer LC, Shaughnessy MA, Paterson R. Modified forms of allergen immunotherapy. J Allergy Qin. Immunol 76, 397–401 (1985).
  • Bousquet J, Lockey R, Malling H J etal Allergen Immunotherapy: Therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Gin. Immunol. 102, 558–562 (1998). Clinical practice immunotherapy recommendation paper.
  • Durham SR, Till SJ. Immunologic changes associated with allergen immunotherapy. Allergy Clin. immunol 102, 157–164 (1998).
  • Ebner C, Siemann U, Bohle B et al. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clone specific for PM p 1, a major grass pollen allergen. Gin. Exp. Allergy27, 1007–1015 (1997).
  • Ball T, Sperr WR, Valent P eta]. Induction of antibody responses to new B-cell epitopes indicates vaccination character of allergen immunotherapy. Eur j Immunol. 29, 2026–2036 (1999).
  • Kay AB. Allergy and Allergic diseases. NEngl. J. Med. 344, 30–37 (2001). Reviews underlying mechanisms of allergy.
  • Rafts-Mills TAE, Mueller GA, Wheatley LM. Future directions for allergen immunotherapy. J Allergy Qin. Immunol 102, 335–343 (1998).
  • Durham SR, Varney VA, Gaga M etal Grass pollen immunotherapy decreases the number of mast cells in the skin. Clin. Allergy29, 1490–1496 (1999).
  • Abramson M, Puy R, Weiner J. Immunotherapy in asthma: an updated systematic review. Allergy54, 1022–1041 (1999).
  • Robinson DS. Th-2 cytokines in allergic disease. Br. Med Bull. 56(4), 956–968 (2000).
  • Focke M et al Nonanaphylactic synthetic peptides derived from B-cell epitotopes of the major grass-pollen allergen, Phi p 1, for allergy vaccination FASEB J. 15, 2045–2047 (2001).
  • van Neerven RJ, Wikborg T, Lund G etal Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T-cells by inhibiting serum-IgE-facilitated allergen presentation. J. Immunol 163, 2944–2955 (1999).
  • Friedhoff LR, Ehrlich-Kautzky E etal. A study of human immune response to Lolium perenne (rye) pollen and its components, Lol p 1 and Lol p 2 (rye I and rye II). 1 Allergy Clin. immunol 78, 1190–1201 (1986).
  • de Weerd, Bhalla PL, Singh MB. Aeroallergens and polliniosis: Molecular and immunological characteristics of cloned pollen allergens. Aembiologia (In Press) (2002).
  • Griffith IJ, Smith P M, Pollock J et al Cloning and sequencing of Lol p 1, the major allergenic protein of rye-grass pollen. FEBS Lett 279, 210–215 (1991).
  • Singh MB, Hough T, Theerakulpisut P etal Isolation of cDNA encoding a newly identified major allergenic protein of rye-grass pollen: Intracellular targeting to the amloplast. Proc. Natl Acad. Sci. USA 88, 1384–1388 (1991).
  • Ong EK, Singh MB, Knox RB Seasonal distribution of pollen in the atmosphere of Melbourne: an airborne pollen calendar. Aerobiologia 11, 219–229 (1995).
  • Suphioglu C, Singh MB, Taylor P etal Mechanism of grass-pollen-induced asthma. Lancet 339, 569–572 (1992).
  • Ong EK, Griffith IJ, Knox RB, Singh MB. Cloning of a cDNA encoding a group-V (group IX) allergen isoform from rye-grass pollen that demonstrates a specific antigenic immunoreactivity. Gene 134, 235–240 (1993).
  • Bhalla PL, Swoboda I, Singh MB. Antisense mediated silencing of a gene encoding a major ryegrass pollen allergen. Proc. Natl Acad. Sc]. USA 96, 11676–11680 (1999).
  • Hirschwehr R, Heppner C, Spitzauer S eta]. Identification of common allergenic structures in mugwort and ragweed pollen. J. Allergy Clin. Immunol. 101, 196–206 (1998).
  • Himly M, Jahn-Schmid B, Dedic A et a/. Art vi, the major allergen of mugwort pollen, is a modular glycoprotein with a defensin-like and a hydroxyproline-rich domain. FASEB express article 10.1096/fj.02-0472fje Published online November 15 (2002).
  • Valenta R, Vrtala S, Laffer S, Spitzauer S, Kraft D. Recombinant allergens. Allergy53, 552–561 (1998).
  • Valenta R, Lidholm J, Niederberger V, Hayek B, Kraft D, Gronlund H. The recombinant allergen-based concept of component resolved diagonsis and immunotherapy (CRD and CRIT). Clin. Exp. Allergy 29, 896–904 (1999).
  • Grammer LC, Shaughnessy MA, Paterson R Modified forms of allergen immunotherapy. J. Allergy Clin. Immunol 76, 397–401 (1985).
  • Hayglass KT, Stefura WP. Anti-IFN gamma treatment blocks the ability of polymerized allergens to inhibit specific IgE responses. J. Exp. Med. 173, 279–287 (1991).
  • Norman PS, Lichtenstein LM, Marsh DG. Studies on allergoids from naturally occuring allergens. IV. Efficacy and safety of long-term allergoid treatment of ragweed hay fever. J. Allergy Clin. Immunol 68, 460–470 (1981).
  • Mohapatra S, Cao Y, Ni H, Salo D. In pursuit of the 'holy grail': recombinant allergens and peptides as catalysts for the allergen specific immunotherapy. Allergy 50\(Suppl. 25), 37–44 (1995).
  • Griffith IJ, Pollock J, Klapper DG, Rogers BL, Nault AK. Sequence polymorphism of Amb a 1 and Amb a 2, the major allergens of Ambrosia artemisifolia (short ragweed). Lit Arch. Allergy Appl Immunol 96, 296–304 (1991).
  • Rafner T, Griffith IJ, Kuo MC, Bond JF, Rogers BL, Klapper DG. Cloning of Amb a 1 (Antigen E), the major allergen family of short ragweed pollen. J. Biol. Chem 266, 1229–1236 (1991).
  • Breiteneder H, Pettenburger K, Bito A eta]. The gene coding for the major birch allergen, Bet v 1, is highly homologous to a pea disease resistance response gene. EMI30 j8, 1935-1938 (1989).
  • Ferreira F, Hirtenlehner K, Jilek A eta]. Dissection of immunoglobulin E and T-lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1. Potential use of hypoallergenic isoforms for immunotherapy. "Exp. Med 183, 599–609 (1996).
  • •Use of naturally occurring isoforms for immunotherapy.
  • Kraft D, Ferreira F, Ebner C eta]. Recombinant allergens: the future of the diagnosis and treatment of atopic allergy. Allergy53, 62–66 (1998).
  • Ferreira F, Ebner C, Kramer B etal. Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy. FASEB J. 12, 231–242 (1998).
  • Esch RE, Klapper DG. Isolation and characterisation of a major cross-reactive grass group-1 antigenic determinant. Md. Immunol 26, 557–561 (1989).
  • Tamborini E, Faccini S, Lidholm J etal. Biochemical and immunological characterization of recombinant allergen Lol p 1. .&,,j Biochem 249, 886–894 (1997).
  • Schramm G, Kahlert H, Suck R eta]. 'Allergen engineering': variants of the timothy grass pollen allergen Phi p 5 with reduced IgE-binding capacity but conserved T-cell reactivity.' Immunol 162, 2406–2414 (1999).
  • Swoboda I, de Weerd N, Bhalla PL etal Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: candidates for grass pollen-specific immunotherapy. Etu: j Immunol. 32, 270–280 (2002).
  • •Construction of lye grass vaccine candidates.
  • Ong EK, Knox RB, Singh MB. Mapping of the antigenic epitopes of Lol p VB using gene fragmentation. Ma immund. 32, 295–302 (1995).
  • Suphioglu C, Blaher B, Rolland JM eta]. B. Molecular basis of IgE-recognition of Lol p 5, a major allergen of ryegrass pollen. Md. Immunol. 35, 293–305 (1998).
  • Blaher B, Suphioglu C, Knox RB, Singh MB, McCluskey J, Rolland JM. Identification of T-cell epitopes of Lol p 9, a major allergen of ryegrass (Lolium perenne) pollen. J. Allergy Clin. Immunol 98, 124–132 (1996).
  • Suphioglu C, Ferreira F, Knox RB. Molecular cloning and immunological characterisation of Cyn d 7, a novel calcium-binding allergen from Bermuda grass pollen. FEBS f Ptt 402, 167–172 (1997).
  • Smith PM, Xu H, Swoboda I, Singh MB Identification of a Ca2+ binding protein as a new Bermuda grass pollen allergen Cyn d 7. IgE cross-reactivity with oilseed rape pollen allergen Bra r 1. Int. Air/i. Allergy Immunol 114, 265–271 (1997).
  • Engel E, Richter K, Obermeyer G et al Immunological and biological properties of Bet v 4, a novel birch pollen allergen with two EF-hand calcium-binding domains. J. Biol. Chem. 272, 28630–28637 (1997).
  • Twardosz A, Hayek B, Seiberler S etal. Molecular characterisation, expression in Escherichia coliand epitope anaylsis of a two EF-hand calcium-binding birch pollen allergen, Bet v 4. Biochem. Biophys. Res. COM1711117. 239, 197–204 (1997).
  • Okada T, Swoboda I, Bhalla PL, Toriyama K, Singh MB. Engineering of hypoallergenic mutants of the Brassica pollen allergen, Bra r 1, for immunotherapy. FERSIett. 434, 255–260 (1998).
  • Valenta R, Hayek B, Seiberler S eta]. Calcium-binding allergens: From plants to man. Lit. Arch. Allergy Immunol 117, 160–166 (1998).
  • Schemer 0, Kraft D. Basic and practical aspects of recombinant allergens. Allergy50, 384–391 (1995).
  • de Weerd N, Bhalla PL Singh MB. Effect of cysteine mutagenesis on human IgE reactivity to a recombinant form of the major rye grass pollen allergen Lol p 1. Allergolgy Int. (In Press).
  • Petersen A, Schramm G, Schlaak M, Becker WM. Post-translational modifications influence IgE reactivity to the major allergen PM p 1 of timothy grass pollen. Clin. Exptl. Allergy28, 315–321 (1998).
  • Visco V, Dolecek C, Denepoux S et al Human monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1. J. Immund 157, 956–962 (1996).
  • Laffer S, Vangelista L, Steinberger P, Kraft D, Pastore A, Valenta R. Molecular characterisation of Bip 1, a monodonal anibody that modulates IgE binding to birch pollen allergen Bet v 1. J. Immunol 157, 4953–4962 (1996).
  • Vrtala S, Hirtenlehner K, Vangelista L eta]. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T-cell epitope-containing fragments: Candidates for a novel form of specific immunotherapy. j Clin. Invest. 99, 1673–1681 (1997).
  • Vrtala S, Hirtenlehner K, Susani M eta]. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1. The FASEB Journal express article 10.1096/fj.00-0767fje. Published online July 24, 2001.
  • •Hypoallergenic forms of tree allergen.
  • Linhart B, Jahn-Schmid B, Verdino P, Keller W Ebner C, Kraft D, Valenta R Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity. FASEB Journal express article 10.1096/fj.00-1012fje. Published online June 21, 2001.
  • Tang Dc, DeVit M, Johnston SA. Genetic immunization is a simple method to eliciting an immune response. Nature 92, 152–154 (1992).
  • Johnston SA, Talaat AM, McGuire MJ. Genetic immunization: What's in a name? Arrh. Med Res. 33, 325–329 (2002).
  • •Reviews limitations and improvement approaches of gene vaccine.
  • Tighe H, Corr M, Roman M, Raz E. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol Today19, 89–97 (1998).
  • Hard A, Kiesslich J, Weiss R etal. Immune responses after immunization with plasmid DNA encoding Bet v 1, the major allergen of birch pollen. J. Allergy Clin. Immunol 103, 107— 113 (1999).
  • Bjorksten B, Moller C, Broberger U et al. Clinical and immunological effects of oral immunotherapy with a standarcii7Pd birch pollen extract. Allergy 41, 90–95 (1986).
  • Moller C, Dreborg S, Lanner A, Bjorksten B. Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. A double-blind study. Allergy 41, 271–279 (1986).
  • Litwin A, Flanagan M, Entis G etal. Oral immunotherapy with short ragweed extract in a novel encapsulated preparation: a double-blind study. J. Allergy Clin. Immunol 100, 30–38 (1997).
  • de Weerd N, Bhalla PL, Singh MB. Oral immunization with a recombinant major grass pollen allergen induces blocking antibodies in mice. Int. Arch. Allergy Immunol (In Press) (2002).
  • Hiller R, Laffer S, Harwanegg C, Huber M, Schmidt WM etal. Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment. The EASES Journal express artide 10.1096/fj .01-0711fje. Published online January 14, 2002.
  • •Demonstration of microarray in allergy diagnosis.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.